Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more
Transcode Therapeutics Inc (RNAZ) - Net Assets
Latest net assets as of September 2025: $1.43 Billion USD
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has net assets worth $1.43 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.23 Billion) and total liabilities ($3.80 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.43 Billion |
| % of Total Assets | 27.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 75.03 |
Transcode Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Transcode Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Transcode Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Transcode Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.02 Million | -223.03% |
| 2023-12-31 | $1.64 Million | -49.37% |
| 2022-12-31 | $3.24 Million | -84.12% |
| 2021-12-31 | $20.40 Million | +698.68% |
| 2020-12-31 | $-3.41 Million | -210.54% |
| 2019-12-31 | $-1.10 Million | -117.77% |
| 2018-12-31 | $-503.97K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Transcode Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6269113900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $103.00 | % |
| Other Components | $61.18 Million | % |
| Total Equity | $-2.02 Million | 100.00% |
Transcode Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Transcode Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UTStarcom Holdings Corp
NASDAQ:UTSI
|
$8.06 Million |
|
Bone Biologics Corp Warrants
NASDAQ:BBLGW
|
$8.06 Million |
|
Elon AB (publ)
ST:ELON
|
$8.06 Million |
|
Urbanise.com Ltd
AU:UBN
|
$8.07 Million |
|
Digital Graphics Incorporation
KQ:043360
|
$8.05 Million |
|
Seamless Distribution Systems AB
ST:SDS
|
$8.05 Million |
|
Avanti Energy Inc
PINK:ARGYF
|
$8.05 Million |
|
BPL Limited
NSE:BPL
|
$8.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Transcode Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,640,814 to -2,018,733, a change of -3,659,547 (-223.0%).
- Net loss of 16,754,971 reduced equity.
- Dividend payments of 30,601,000 reduced retained earnings.
- New share issuances of 16,401,174 increased equity.
- Other factors increased equity by 27,295,250.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.75 Million | -829.97% |
| Dividends Paid | $30.60 Million | -1515.85% |
| Share Issuances | $16.40 Million | +812.45% |
| Other Changes | $27.30 Million | +1352.1% |
| Total Change | $- | -223.03% |
Book Value vs Market Value Analysis
This analysis compares Transcode Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-2621.96 | $9.68 | x |
| 2019-12-31 | $-171.30 | $9.68 | x |
| 2020-12-31 | $-427.15 | $9.68 | x |
| 2021-12-31 | $1264.99 | $9.68 | x |
| 2022-12-31 | $199.78 | $9.68 | x |
| 2023-12-31 | $302.49 | $9.68 | x |
| 2024-12-31 | $-5.67 | $9.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Transcode Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-243.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-403.04K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-497.46K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.00 Million |
| 2021 | -33.54% | 0.00% | 0.00x | 1.12x | $-8.88 Million |
| 2022 | -542.01% | 0.00% | 0.00x | 2.34x | $-17.89 Million |
| 2023 | -1130.30% | 0.00% | 0.00x | 3.15x | $-18.71 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.55 Million |
Industry Comparison
This section compares Transcode Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Transcode Therapeutics Inc (RNAZ) | $1.43 Billion | 0.00% | 2.67x | $8.06 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |